Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
IPO Year: 2022
Exchange: NASDAQ
Website: https://belitebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $194.00 | Neutral → Outperform | Mizuho |
| 11/24/2025 | $154.00 | Overweight | Cantor Fitzgerald |
| 11/20/2025 | $105.00 | Neutral | Mizuho |
| 12/14/2023 | $60.00 | Buy | Maxim Group |
| 7/28/2023 | $43.00 | Overweight | Cantor Fitzgerald |
| 7/26/2023 | $25.00 | Outperform | SVB Securities |
| 8/1/2022 | $58.00 | Buy | H.C. Wainwright |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00
Cantor Fitzgerald resumed coverage of Belite Bio with a rating of Overweight and set a new price target of $154.00
Mizuho initiated coverage of Belite Bio with a rating of Neutral and set a new price target of $105.00
Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00
Cantor Fitzgerald initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $43.00
SVB Securities initiated coverage of Belite Bio with a rating of Outperform and set a new price target of $25.00
H.C. Wainwright initiated coverage of Belite Bio with a rating of Buy and set a new price target of $58.00
424B5 - BELITE BIO, INC (0001889109) (Filer)
6-K - BELITE BIO, INC (0001889109) (Filer)
424B5 - BELITE BIO, INC (0001889109) (Filer)
6-K - BELITE BIO, INC (0001889109) (Filer)
6-K - BELITE BIO, INC (0001889109) (Filer)
6-K - BELITE BIO, INC (0001889109) (Filer)
6-K - BELITE BIO, INC (0001889109) (Filer)
F-3ASR - BELITE BIO, INC (0001889109) (Filer)
144 - BELITE BIO, INC (0001889109) (Subject)
6-K - BELITE BIO, INC (0001889109) (Filer)
Fastest customizable press release news feed in the world
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the Company at the public offering price, less underwriting discounts and commissions. The gross proceeds
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addition, Belite Bio intends to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price, less underwriting discounts and commission. The offering is subject t
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite
Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full warrant exerciseCompleted pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025China's NMPA has agreed to accept New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results of DRAGON trialUK's MHRA has agreed to accept Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held November 4th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. November 4th Company Presentations HUTCHMED (China) Limited(AIM: HCM, NASDAQ:HCM, and HKEX:13)First Pacific Company Ltd((HKEX: 142, OTC:FPAFY)Viomi Technology Co., Ltd(NASDAQ:VIOT)Epiroc AB((Nasdaq Stockholm: EPIA, OTC:EPO
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, November 10, 2025Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link: https://events.q4inc.com/attendee/847711723 Webcast Link InstructionsYou can join the live webcast by visiting the li
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has agreed to accept a Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial. "We are extremely pleased with the outcome of our eng
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows: Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The conference is targeted to all categories
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Netherlands, Denmark, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pre
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hao-Yuan Chuang, Chief Financial Officer, will present live at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com, on November 4th, 2025. This virtual conference program is aimed exclusively at introducing global companies with ADR programs to investors. DATE: November 4th TIME: 10:30 am LINK: REGISTER HERE This will be a live,
Live Leadership Updates
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar
This live feed shows all institutional transactions in real time.
SC 13G - BELITE BIO, INC (0001889109) (Subject)
SC 13G - BELITE BIO, INC (0001889109) (Subject)
SC 13G - BELITE BIO, INC (0001889109) (Subject)
SC 13G - BELITE BIO, INC (0001889109) (Subject)
Live finance-specific insights
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,
Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET
In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease ("STGD1") trial ("LBS-008-CT02"), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjectsA continued trend of slowing expansion of autofluorescence was observed and the growth rate of incident atrophic retinal lesions was reduced with Tinlarebant in LBS-008-CT02 compared to a natural history study of the disease ("ProgStar")Stabilization of visual acuity with no significant loss and no clinically significant changes in retinal thickness observed over 18 months of treatment with Tinlarebant in LBS-008-CT0258 subjects have been enrolled in the pivotal Phase 3 "DRAGON" trial eva
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company's financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday, August 10, 2022. Belite Bio, Inc First Half 2022 Financial Result Conference Call Information: Date:Thursday, August 11, 2022Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast Link:https://edge.media-server.com/mmc/p/d